Tags

Type your tag names separated by a space and hit enter

Could colorimetric method replace the individual minimal erythemal dose (MED) measurements in determining the initial dose of narrow-band UVB treatment for psoriasis patients with skin phototype III-V?
J Eur Acad Dermatol Venereol. 2013 Apr; 27(4):494-8.JE

Abstract

BACKGROUND

Assessment of minimal erythemal dose (MED) for individual patients has been used to guide the narrowband Ultraviolet B (NB-UVB) phototherapy, which sometimes causes discomfort and additional time. The L* value (the lightness of color in Commission Internationlale de l'Eclairge L*a*b* color scale) measured by colorimeter was shown to be useful for predicting sensitivity to NB-UVB irradiation.

OBJECTIVE

To compare the efficacy and safety of NB-UVB phototherapy between 50% of MED and colorimetric L* value starting dose regimens for skin phototype III-V Korean patients with psoriasis.

METHOD

Twenty seven patients determined starting doses based on colorimetric L* value, and 27 patients based on 50% of MED. Since correlation analysis showed that L* value had the most significant association with MED compared with skin phototypes, a*, and b* values, we designated starting doses of L* value regimen as follows: 300 mJ/cm(2) (L* >66), 400 mJ/cm(2) (62 < L* ≤ 66), and 500 mJ/cm(2) (L* ≤ 62).

RESULTS

There was no significant difference between two groups in clinical efficacy including response rate, mean number of sessions, duration of treatment, maximum dose and cumulative dose until achieving the state of near clearance. The proportion of adverse effects was not also significantly different.

CONCLUSIONS

NB-UVB starting dose determination based on colorimetric L* value was comparable with conventional MED based regimen in efficacy and safety for skin phototype III-V patients. Since it provides much convenience and ease for both patients and physicians, colorimetric L* value could partly substitute the MED checking methods in NB-UVB phototherapy.

Authors+Show Affiliations

Department of Dermatology, Seoul National University College of Medicine, Seoul, Korea.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

22340091

Citation

Kwon, I H., et al. "Could Colorimetric Method Replace the Individual Minimal Erythemal Dose (MED) Measurements in Determining the Initial Dose of Narrow-band UVB Treatment for Psoriasis Patients With Skin Phototype III-V?" Journal of the European Academy of Dermatology and Venereology : JEADV, vol. 27, no. 4, 2013, pp. 494-8.
Kwon IH, Kwon HH, Na SJ, et al. Could colorimetric method replace the individual minimal erythemal dose (MED) measurements in determining the initial dose of narrow-band UVB treatment for psoriasis patients with skin phototype III-V? J Eur Acad Dermatol Venereol. 2013;27(4):494-8.
Kwon, I. H., Kwon, H. H., Na, S. J., & Youn, J. I. (2013). Could colorimetric method replace the individual minimal erythemal dose (MED) measurements in determining the initial dose of narrow-band UVB treatment for psoriasis patients with skin phototype III-V? Journal of the European Academy of Dermatology and Venereology : JEADV, 27(4), 494-8. https://doi.org/10.1111/j.1468-3083.2012.04471.x
Kwon IH, et al. Could Colorimetric Method Replace the Individual Minimal Erythemal Dose (MED) Measurements in Determining the Initial Dose of Narrow-band UVB Treatment for Psoriasis Patients With Skin Phototype III-V. J Eur Acad Dermatol Venereol. 2013;27(4):494-8. PubMed PMID: 22340091.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Could colorimetric method replace the individual minimal erythemal dose (MED) measurements in determining the initial dose of narrow-band UVB treatment for psoriasis patients with skin phototype III-V? AU - Kwon,I H, AU - Kwon,H H, AU - Na,S J, AU - Youn,J I, Y1 - 2012/02/20/ PY - 2012/2/21/entrez PY - 2012/2/22/pubmed PY - 2013/9/10/medline SP - 494 EP - 8 JF - Journal of the European Academy of Dermatology and Venereology : JEADV JO - J Eur Acad Dermatol Venereol VL - 27 IS - 4 N2 - BACKGROUND: Assessment of minimal erythemal dose (MED) for individual patients has been used to guide the narrowband Ultraviolet B (NB-UVB) phototherapy, which sometimes causes discomfort and additional time. The L* value (the lightness of color in Commission Internationlale de l'Eclairge L*a*b* color scale) measured by colorimeter was shown to be useful for predicting sensitivity to NB-UVB irradiation. OBJECTIVE: To compare the efficacy and safety of NB-UVB phototherapy between 50% of MED and colorimetric L* value starting dose regimens for skin phototype III-V Korean patients with psoriasis. METHOD: Twenty seven patients determined starting doses based on colorimetric L* value, and 27 patients based on 50% of MED. Since correlation analysis showed that L* value had the most significant association with MED compared with skin phototypes, a*, and b* values, we designated starting doses of L* value regimen as follows: 300 mJ/cm(2) (L* >66), 400 mJ/cm(2) (62 < L* ≤ 66), and 500 mJ/cm(2) (L* ≤ 62). RESULTS: There was no significant difference between two groups in clinical efficacy including response rate, mean number of sessions, duration of treatment, maximum dose and cumulative dose until achieving the state of near clearance. The proportion of adverse effects was not also significantly different. CONCLUSIONS: NB-UVB starting dose determination based on colorimetric L* value was comparable with conventional MED based regimen in efficacy and safety for skin phototype III-V patients. Since it provides much convenience and ease for both patients and physicians, colorimetric L* value could partly substitute the MED checking methods in NB-UVB phototherapy. SN - 1468-3083 UR - https://www.unboundmedicine.com/medline/citation/22340091/Could_colorimetric_method_replace_the_individual_minimal_erythemal_dose__MED__measurements_in_determining_the_initial_dose_of_narrow_band_UVB_treatment_for_psoriasis_patients_with_skin_phototype_III_V L2 - https://doi.org/10.1111/j.1468-3083.2012.04471.x DB - PRIME DP - Unbound Medicine ER -